Bio-Techne (NasdaqGS:TECH) Q2 2026 Earnings call February 04, 2026 09:00 AM ET Company ParticipantsBrandon Couillard - Managing DirectorDan Arias - Managing DirectorDavid Clair - VP of Investor RelationsJim Hippel - CFOKim Kelderman - President and CEOPatrick Donnelly - Managing Director of Equity ResearchConference Call ParticipantsDan Leonard - Managing Director of Research AnalystMatt Larew - AnalystPuneet Souda - Senior Research AnalystNone - AnalystOperatorThank you for your continued patience. Your me ...

Bio-Techne (NasdaqGS:TECH) Q2 2026 Earnings call February 04, 2026 09:00 AM ET Speaker3Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time throughout the event today, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time throughout the call today, please press star zero and a member of our team will be happy to help you. Good m ...

Summary of Bio-Techne (TECH) 2025 Conference Call Company Overview - **Company**: Bio-Techne (TECH) - **Date**: May 13, 2025 - **Key Speakers**: Kim Kelderman (CEO), Jim Hipple (CFO) Key Highlights Financial Performance - **Fiscal 3Q Results**: Reported a solid 6% growth despite macroeconomic headwinds [3][4] - **Protein Sciences Segment**: Achieved 7% growth, driven by core reagents and instrumentation for protein detection [4] - **Diagnostics and Special Segment**: Growth was muted at 2%, influenced by timing of orders rather than market conditions [5][6] - **EBITDA Margins**: Maintained strong margins at 34.9%, reflecting operational efficiencies [6] Market Exposure and Headwinds - **U.S. Academic Exposure**: 21% of revenues from academic business, with 12% from U.S. academic institutions [7] - **NIH Funding Impact**: Approximately 50% of academic revenue is exposed to NIH funding, which has created uncertainty [8] - **Consumables vs. Equipment**: Consumables (80% of business) remained steady, while equipment sales were more volatile due to budget uncertainties [10] Regulatory and Policy Environment - **Tariff Exposure**: Estimated exposure of $20 million from tariffs, but proactive measures have mitigated this risk [24][25] - **Biopharma Sector**: Comprises 50% of revenues, with large pharma showing double-digit growth while biotech remained flat due to funding challenges [35][38] Strategic Focus - **Cell and Gene Therapy**: Significant focus on GMP reagents, with a strong pipeline of customers in clinical studies [46][48] - **Spatial Business**: Competitive instruments showing double-digit growth, leveraging a large reagent portfolio [52][53] - **M&A Strategy**: Continued focus on acquisitions that align with high-margin reagent sales, with a disciplined approach to valuation [56][57] Future Outlook - **Q4 Expectations**: Anticipated continued uncertainty, with large pharma expected to drive growth while biotech remains challenged [60][61] - **Fiscal Year 2026 Guidance**: Uncertainty prevails, with hopes for stabilization in the coming months to provide clearer guidance [62][63] Additional Insights - **Market Dynamics**: The consolidation in the research reagents market has changed competitive dynamics, but the company remains well-positioned due to its strong portfolio and technical sales force [42][44] - **Regulatory Discussions**: Positive sentiment around cell and gene therapies, with a focus on maintaining high regulatory standards to avoid negative industry impacts [49][50] This summary encapsulates the key points discussed during the Bio-Techne conference call, highlighting the company's performance, market challenges, strategic initiatives, and future outlook.